ArticleGlobal health action2025
Serological survey to determine measles and rubella immunity gaps across age and geographic locations in The Gambia: a study protocol.
Article in Global health action, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Vaccine coverage and disease surveillance data are valuable for monitoring protection against vaccine-preventable diseases; however, they do not directly measure population immunity. High-quality, representative serological studies can provide key insights into immunity gaps, outbreak susceptibility, and inform targeted vaccination strategies, even in high-performing immunization programs. This study aims to estimate location-specific and age-specific immunity profiles for measles and rubella while evaluating the predictive value of indirect immunity estimates derived from vaccination and surveillance data against direct serological measurements. Additionally, it seeks to model the risk of measles outbreaks and assess the impact of mitigation strategies. A multi-stage, stratified cluster sampling design will be implemented across six districts in The Gambia's North Bank and Upper River Regions. Survey clusters (i.e. 5 km × 5 km areas) encompassing all settlements within their boundaries will be selected, proportionally to district population sizes. Cluster selection ensures representativeness of both the population and vaccine coverage within each district. Based on detecting a 10% difference in protective immunity across vaccine coverage levels, power analysis assumes an intraclass correlation coefficient (ICC) of 0.01. In each cluster, 70 children aged 9 months to 14 years will be recruited, yielding a total sample size of 1,750 children across 25 selected clusters. Dried blood samples will be collected and tested for anti-measles and anti-rubella IgG using enzyme immunoassays (EIA). District-specific measles seroprevalence will be estimated using a hierarchical spatial model. This study will generate key evidence needed to refine immunization strategies and reduce the risk of measles and rubella outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.